Millipore Sigma Vibrant Logo
 
プレスリリース
前のページへ戻る
 


News Release
April 18, 2018
Your Contact:
Karen Tiano +49 6151 72 44461
Merck Wins INTERPHEX Exhibitor Award for Best Technological Innovation
  • Award recognizes new, fully synthetic clarification filter
  • Millistak+® HC Pro portfolio of depth filters improves capacity, reducing footprint by up to 2x for primary clarification

Darmstadt, Germany, April 18, 2018 — Merck, a leading science and technology company, today announced that its Millistak+® HC Pro portfolio has won an INTERPHEX Exhibitor Award for Best Technological Innovation.

“Merck is dedicated to delivering innovations that bring advanced drug therapies to market, faster,” said Andrew Bulpin, head of the Process Solutions business unit, Life Science, at Merck. “As the first fully synthetic depth filters, Merck’s Millistak+® HC Pro portfolio provides as much as twice the filtration capacity as commercial diatomaceous earth (DE)-based benchmarks and offers customers greater productivity and speed with reduced risk. We are honored to be recognized for this advancement in biopharmaceutical manufacturing.”

Merck’s Millistak+® HC Pro portfolio is a family of synthetic depth filters providing cleaner, more consistent depth filtration media than other DE- and cellulose-based filter offerings. Made with entirely synthetic materials, Millistak+® HC Pro filters eliminate naturally derived components from the clarification process, resulting in increased productivity with less flushing.

Merck’s Process Solutions business unit provides the industry’s most comprehensive portfolio of high-quality products and services for biopharmaceutical manufacturing.

For biopharmaceutical manufacturers, Merck’s depth filter reduces total organic carbon extractables and pre-use flush volume by 50 percent. The filter also eliminates the potential for beta glucans, which can interfere with limulus amebocyte lysate testing used to detect and quantify bacterial endotoxins. The unparalleled lot-to-lot consistency helps biopharmaceutical manufacturers design a more robust clarification process.

Merck is showcasing this industry-leading portfolio at Booth 2841 at INTERPHEX, which runs through tomorrow at the Javits Center, New York City.

For more information on Merck’s Millistak+® HC Pro, visit www.merckmillipore.com/Millistack+HCPro.

メルクについて
Merck（メルク）はヘルスケア、ライフサイエンス、パフォーマンスマテリアルズの分野における世界有数のサイエンスとテクノロジー企業です。がんや多発性硬化症のためのバイオ医薬品を用いた治療法から、科学研究と生産に関する最先端システム、スマートフォンや液晶テレビ向けの液晶材料にいたるまで、約53,000人の従業員が人々の暮らしをより良くする技術の一層の進歩を目指しています。2017年は66カ国で153億ユーロの売上高を計上しました。

メルクは1668年に創業された世界で最も歴史の長い医薬・化学品会社で、 創業家が今でも、上場企業が率いるメルクグループの株式の過半数を所有しています。メルクの名称およびブランドのグローバルな権利は、メルクが保有しています。唯一の例外は米国とカナダで、両国ではEMDセローノ、ミリポアシグマ、EMDパフォーマンスマテリアルズとして事業を行っています。